Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | ATIC | P31939 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30838807 | 0.98 | GDA (0.32) | GDA | |
| SCHEMBL1338837 | 0.68 | ALDH1A1 (0.31) | ALDH1A1POLBRXFP1ATIC | |
| SCHEMBL9049462 | 0.65 | ALDH1A1 (0.32) | GDAALDH1A1POLBRXFP1ATIC | |
| SCHEMBL905427 | 0.64 | PNP (0.31) | GDAALDH1A1 | |
| SCHEMBL4748766 | 0.64 | ALDH1A1 (0.31) | ALDH1A1POLBRXFP1ATIC | |
| SCHEMBL17425088 | 0.63 | ALDH1A1 (0.30) | ALDH1A1POLBRXFP1ATIC | |
| SCHEMBL15414257 | 0.62 | GDA (0.42) | GDAALDH1A1POLBRXFP1ATIC | |
| SCHEMBL8011952 | 0.58 | GDA (0.38) | GDAALDH1A1POLBRXFP1ATIC | |
| SCHEMBL4455591 | 0.56 | — | — | |
| SCHEMBL10612254 | 0.55 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250076302-A1 | DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES | THE CLEVELAND CLINIC FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| US-20250052717-A1 | METHODS AND DEVICES FOR SEQUENCING NUCLEIC ACIDS IN SMALLER BATCHES | QIAGEN SCIENCES, LLC | 2025-02-13 | — | — | US | disclosed |
| EP-4367235-A1 | COMPOSITIONS AND METHODS FOR DETECTING GENETIC FEATURES | Singular Genomics Systems, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11940413-B2 | Methods and devices for sequencing nucleic acids in smaller batches | IsoPlexis Corporation (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN SCIENCES, LLC | 2024-03-07 | — | — | US | disclosed |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2024-02-22 | — | — | US | disclosed |
| EP-4271839-A1 | PHASE PROTECTIVE REAGENT FLOW ORDERING | Singular Genomics Systems, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022197942-A9 | PHASE PROTECTIVE REAGENT FLOW ORDERING | Singular Genomics Systems, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023283090-A1 | COMPOSITIONS AND METHODS FOR DETECTING GENETIC FEATURES | Singular Genomics Systems, Inc. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022272150-A2 | LINKED TRANSCRIPT SEQUENCING | Singular Genomics Systems, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022197942-A1 | PHASE PROTECTIVE REAGENT FLOW ORDERING | Singular Genomics Systems, Inc. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4055023-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | GDA 92/4885ALDH1A1 4837/4885POLB 44/4885 |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | GDA 92/4885ALDH1A1 4837/4885POLB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.